Purpose: To investigate a new sustained-release formulation of dexamethasone (Ozurdex®) for inhibiting proliferative vitreoretinopathy (PVR) and its effect on the expression of retinal glial reaction and inflammation in experimental PVR eyes. Methods: We used 30 pigmented rabbits for this study. One week after gas compression, the eyes were injected with 5 × 104 retinal pigment epithelial cells into the vitreous cavity to induce PVR. Concurrently, one eye also received an intravitreal injection of Ozurdex; the other eye was used as a control. PVR was graded by indirect ophthalmoscopy on days 1, 3, 7, 14, 21, and 28. The expression of the retinal glial reaction and inflammation in experimental PVR eyes were evaluated by Western blot analysis. Results: PVR severity increased gradually and peaked after 14 days, and no differences in PVR severity between the study and control groups were observed at any time point. The expression of glial fibrillary acid protein (GFAP) increased on days 7 and 14 in both the PVR control and study groups. While the use of Ozurdex in the study group showed less GFAP expression, this difference was not significant. The expression of tumor necrosis factor (TNF)-α and interleukin (IL)-6 significantly increased on days 7 and 14 in PVR control eyes. There was a significant difference in TNF-α between PVR control eyes and Ozurdex-treated eyes on days 7 (p < 0.001) and 14 (p = 0.019). Ozurdex in the study group showed lower IL-6 expression; however, this difference was not significant on days 7 (p = 0.063) and 14 (p = 0.052). Conclusions: The intravitreal injection of Ozurdex suppressed the expression of inflammatory markers; however, it did not mitigate the severity of experimental PVR in this animal model.

Keywords:
Proliferative vitreoretinopathy, Steroid, Ozurdex®, Inflammation
1.
Heimann H, Bartz-Schmidt KU, Bornfeld N, Weiss C, Hilgers RD, Foerster MH; Scleral Buckling versus Primary Vitrectomy in Rhegmatogenous Retinal Detachment Study Group: Scleral buckling versus primary vitrectomy in rhegmatogenous retinal detachment: a prospective randomized multicenter clinical study. Ophthalmol 2007;114:2142-2154.
2.
Falkner-Radler CI, Myung JS, Moussa S, Chan RVP, Smretschnig E, Kiss S, Graf A, D'Amico DJ, Binder S: Trends in primary retinal detachment surgery: results of a bicenter study. Retina 2011;31:928-936.
3.
The Retina Society Terminology Committee: The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmol 1983;90:121-125.
4.
Vinores SA, Campochiaro PA, Conway BP: Ultrastructural and electron-immunocytochemical characterization of cells in epiretinal membranes. Invest Ophthalmol Vis Sci 1990;31:14-28.
5.
Machemer R, van Horn D, Aaberg TM: Pigment epithelial proliferation in human retinal detachment with massive periretinal proliferation. Am J Ophthalmol 1978;85:181-191.
6.
Morino I, Hiscott P, McKechnie N, Grierson I: Variation in epiretinal membrane components with clinical duration of the proliferative tissue. Br J Ophthalmol 1990;74:393-399.
7.
Sethi CS, Lewis GP, Fisher SK, Leitner WP, Mann DL, Luthert PJ, Charteris DG: Glial remodeling and neural plasticity in human retinal detachment with proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2005;46:329-342.
8.
Fisher SK, Erickson PA, Lewis GP, Anderson DH: Intraretinal proliferation induced by retinal detachment. Invest Ophthalmol Vis Sci 1991;32:1739-1748.
9.
Geller SF, Lewis GP, Anderson DH, Fisher SK: Use of the MIB-1 antibody for detecting proliferating cells in the retina. Invest Ophthalmol Vis Sci 1995;36:737-744.
10.
Kirmani M, Santana M, Sorgente N: Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy. Retina 1983;3:269-272.
11.
Tano Y, Sugita G, Abrams G, Machemer R: Inhibition of intraocular proliferation with intravitreal corticosteroids. Am J Ophthalmol 1980;89:131-136.
12.
Wiedemann P, Hilgi RS, Bauer P, Heimann K: Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Am J Ophthalmol 1998;126:550-559.
13.
Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, Aylward GW: Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology 2001;108:1179-1183.
14.
Kuo HK, Wu PC, Yang PM, Chen YH, Wu YC, Hu DN: Effects of topoisomerase II inhibitors on retinal pigment epithelium and experimental proliferative vitreoretinopathy. J Ocul Pharmacol Ther 2007;23:15-20.
15.
Kuo HK, Chen YH, Wu PC, Wu YC, Huang F, Kuo CW, Lo LH, Shiea J: Attenuated glial reaction in experimental proliferative vitreoretinopathy treated with liposomal doxorubicin. Invest Ophthalmol Vis Sci 2012;53:3167-3174.
16.
Yang CS, Khawly JA, Hainsworth DP, Chen SN, Ashton P, Guo H, Jaffe GJ: An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol 1998;116:69-77.
17.
Cheema RA, Peyman GA, Fang T, Jones A, Lukaris AD, Lim K: Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy. Ophthalmic Surg Lasers Imaging 2007;38:365-370.
18.
Ahmadieh H, Feghhi M, Tabatabaei H, Shoeibi N, Ramezani A, Mohebbi MR: Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial. Ophthalmol 2008;115:1938-1943.
19.
Dehghan MH, Ahmadieh H, Soheilian M, Azarmina M, Moradian S, Ramezani AR, Tavallal A, Naghibozakerin J: Effect of oral prednisolone on visual outcome and complications after scleral buckling. Eur J Ophthalmol 2010;20:419-423.
20.
Ryan SJ: Traction retinal detachment. XLIX Edward Jackson Memorial Lecture. Am J Ophthalmol 1993;115:1-20.
21.
Weller M, Wiedemann P, Heimann K: Proliferative vitreoretinopathy - is it anything more than wound healing at the wrong place? Int Ophthalmol 1990;14:105-117.
22.
Nagasaki H, Shinagawa K, Mochizuki M: Risk factors for proliferative vitreoretinopathy. Prog Retin Eye Res 1998;17:77-98.
23.
Schweigerer L, Malerstein B, Neufeld G, Gospodarowicz D: Basic fibroblast growth factor is synthesized in cultured retinal pigment epithelial cells. Biochem Biophys Res Commun 1987;143:934-940.
24.
Tanihara H, Yoshida M, Matsumoto M, Yoshimura N: Identification of transforming growth factor-β expressed in cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1993;34:413-419.
25.
Planck SR, Dang TT, Graves D, Tara D, Ansel JC, Rosenbaum JT: Retinal pigment epithelial cells secrete interleukin-6 in response to interleukin-1. Invest Ophthalmol Vis Sci 1992;33:78-82.
26.
Tanihara H, Yoshida M, Yoshimura N: Tumor necrosis factor-α gene is expressed in stimulated retinal pigment epithelial cells in culture. Biochem Biophys Res Commun 1992;187:1029-1034.
27.
Kirchhof B, Kirchhof E, Ryan SJ, Dixon JFP, Barton BE, Sorgente N: Macrophage modulation of retinal pigment epithelial cell migration and proliferation. Graefes Arch Clin Exp Ophthalmol 1989;227:60-66.
28.
Esser P, Heimann K, Wiedemann P: Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulation. Br J Ophthalmol 1993;77:731-733.
29.
Blumenkranz MS, Claflin A, Hajek AS: Selection of therapeutic agents for intraocular proliferative disease. Cell culture evaluation. Arch Ophthalmol 1984;102:598-604.
30.
Tung IC, Wu WC, Kao YH, Chang YC, Chung CH, Hu DN: The effect of combined 5-fluorouracil and dexamethasone on cultured human retinal pigment epithelial cells. Kaohsiung J Med Sci 2001;17:524-529.
31.
Wu WC, Kao YH, Hu DN: A comparative study of effects of antiproliferative drugs on human retinal pigment epithelial cells in vitro. J Ocul Pharmacol Ther 2002;18:251-264.
32.
Oh J, Jung YS, Kim GS, Oh IK, Rho BK, Huh K: The effect of short-term exposure of triamcinolone acetonide on fibroblasts and retinal pigment epithelial cells. Acta Ophthalmol Scand 2007;85:786-790.
33.
Miura Y, Roider J: Triamcinolone acetonide prevents oxidative stress-induced tight junction disruption of retinal pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol 2009;247:641-649.
34.
Weijtens O, Feron EJ, Schoemaker RC, et al: High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol 1999;128:192-197.
35.
Weijtens O, Schoemaker RC, Lentjes EG, Romijn FP, Cohen AF, van Meurs JC: Dexamethasone concentration in the subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose. Ophthalmol 2000;107:1932-1938.
36.
Matsuda S, Gomi F, Oshima Y, Tohyama M, Tano Y: Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol Vis Sci 2005;46:1062-1068.
37.
Koerner F, Koerner-Stiefbold U, Garweg JG: Systemic corticosteroids reduce the risk of cellophane membranes after retinal detachment surgery: a prospective randomized placebo-controlled double-blind clinical trial. Graefes Arch Clin Exp Ophthalmol 2012;250:981-987.
38.
Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, Welty D: Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011;52:80-86.
39.
Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J; the OZURDEX GENEVA Study Group: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-1146.
40.
Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM; the Ozurdex HURON Study Group: Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011;129:545-553.
41.
Bhagat R, Zhang J, Farooq S, Li XY: Comparison of the release profile and pharmacokinetics of intact and fragmented dexamethasone intravitreal implants in rabbit eyes. J Ocul Pharmacol Ther 2014;30:854-858.
42.
Banerjee PJ, Bunce C, Charteris DG: Ozurdex® (a slow-release dexamethasone implant) in proliferative vitreoretinopathy: study protocol for a randomised controlled trial. Trials 2013;14:358.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.